Chesterfield-based biotech firm Commonwealth Biotechnologies has had its shares delisted from the Nasdaq Stock Market after it was unable to meet a minimum stockholders’ equity of $2.5 million by Jan. 20.
Nasdaq suspended trading of the company’s shares, which traded under the symbol CBI, effective Sunday morning. The company first received notice it was in danger of being delisted in July.
The company may request a review hearing within 15 days.
According to a notice filed by Commonwealth Biotechnologies, the company is seeking to list its shares on the OTC Bulletin Board.
Last year, the company sold two of its divisions to Bostwick Laboratories for $1.11 million. Also last year, the company acquired a group of Chinese-based companies.
